The combination Metformin + Sulfonylurea (Glimipiride belongs to class Sulfonylurea) is recommended by Global Bodies as the First line of Choice in the management of Type 2 Diabetes.
Glimipiride functions by stimulating the insulin release from beta cells (beta cells are present in Pancreas) and inhibits gluconeogenesis (generation of glucose)
at hepatic (Liver) cells. It also increases insulin sensitivity at peripheral target sites.
Metformin decreases hepatic gluconeogenesis, decreases intestinal absorption of glucose and improves insulin sensitivity (increases peripheral glucose uptake and utilisation).
Intas ranks 11th in the Indian pharmaceutical market. It is a leading, global pharmaceutical formulation development, manufacturing and marketing company headquartered in India. Intas operates in more than 80 countries globally. The company is known for its range of products in Oncology and other hospital based therapeutic segments in the EU and US.
Zoryl-M is prescribed to patients with Type-2 Diabetes.
Blood glucose is the main source of energy and it comes from the food one consumes. Pancreas produces a hormone called insulin, which helps convert the glucose from food to energy by carrying it inside body cells.
Diabetes mellitus, commonly known as diabetes, is a disease that increases sugar levels in blood. With diabetes, body either doesn’t make enough insulin or can’t effectively use the insulin it does make. This increases the level of unutilised glucose in the blood.
Glucose then accumulates in blood and doesn’t reach cells causing a lot of health problems and diseases that may include:
Diabetes is a chronic disease that can be controlled with a healthy life style and medication.
Concomitant admin with propranolol increases Cmax, AUC, and T1/2 of glimepiride. Aspirin increases the mean AUC of glimepiride. Furosemide increases the Cmax of metformin.
Potentially Fatal: NSAIDS, salicylates, sulfonamides, chloramphenicol, coumarins, probenecid, MAOs, and beta blockers potentiate the hypoglycemic action of glimepiride.
Mechanism of Action
Glimepiride stimulates the insulin release from functioning pancreatic β-cells and inhibits gluconeogenesis at hepatic cells. It also increases insulin sensitivity at peripheral target sites. Metformin decreases hepatic gluconeogenesis, decreases intestinal absorption of glucose and improves insulin sensitivity (increases peripheral glucose uptake and utilisation).